GCL Pharma produces plastic, rubber and aluminium closures for pharmaceutical applications. Credit: Wolfgang Mennel from Pixabay.

Pharmaceutical packaging company Bormioli Pharma has issued a binding offer to acquire 100% stake in GCL Pharma, an Italian subsidiary of Guala Closures Group.

The offer carries an aggregate purchase price of €8.9m.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Based in the Italian city of Vasto, GCL Pharma produces plastic, rubber and aluminium closures for pharmaceutical applications.

Last year, the company reported an annual turnover of €8m.

With this acquisition, Bormioli Pharma seeks to further consolidate its position as a pharmaceutical glass and plastic primary packaging provider and strengthen its product portfolio.

Bormioli Pharma CEO Andrea Lodetti said: “With the acquisition of GCL Pharma, we will continue our growth path.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We aim to strengthen our industrial footprint by adding new technologies that allow to extend our product range, especially in the oral and parenteral segments, activating further business synergies.”

The divestment will help Guala Closures Group to focus on its core business. The company operates 30 production plants and markets its products in more than 100 countries.

Guala Closure Group chairman and CEO Marco Giovannini said: “This disposal will allow the Guala Closures Group to fully-focus on its core business, and specifically on high value closures with increased growth prospective, including connected closures.”

The transaction is expected to close in the following few weeks. It follows Bormioli Pharma’s acquisition of German company Remy & Geiser in October last year.

With two manufacturing facilities, Remy & Geiser provides plastic and glass primary packaging solutions to the pharmaceutical industry.

Its product portfolio includes closure, dosing systems, pipette droppers and tubular glass vials.